Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Dec 8, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called drug-eluting vertebral artery stenting, which is designed for patients with a narrowing of the vertebral arteries due to plaque buildup, a condition known as atherosclerosis. This narrowing can lead to serious issues like ischemic strokes, which occur when blood flow to the brain is reduced. The trial aims to observe how well this stenting procedure works in real-world settings. Participants will be monitored over three years, with check-ins at 30 days, 6 months, 12 months, and then annually.

To be eligible for this trial, participants need to be at least 18 years old and must be able to receive a specific type of stent that releases a medication called rapamycin. It's important that both the patients and their families fully understand the trial and agree to take part by signing a consent form. However, some individuals may not qualify if they have certain health issues, such as severe infections, uncontrolled high blood pressure, or recent heart or brain problems. Participants can expect regular follow-ups to assess their health and the effectiveness of the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old, gender is not limited;
• • 2. Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems;
• • 3. Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form.
• Exclusion Criteria:
• • 1. Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery;
• • 2. With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery;
• • 3. Gastrointestinal disease with active bleeding;
• • 4. Previous myocardial infarction or large-scale cerebral infarction within 2 weeks;
• • 5. Known contraindications to heparin, rapamycin, anesthesia, and contrast agents;
• • 6. Life expectancy less than 12 months;
• • 7. the investigator judged patients to be unsuitable for participation in this study.

Trial Officials